Genetic Technologies Limited (ADR) (NASDAQ:GENE)

CAPS Rating: 1 out of 5

A biotechnology company, pursuing commercial opportunities in: out-licensing its non-coding patents globally; expanding genetic service-testing business in the Asia-Pacific Region; & supporting research projects in which it is already involved.

Results 1 - 8 of 8

Recs

0
Member Avatar ihopeso (< 20) Submitted: 11/23/2015 4:55:25 PM : Outperform Start Price: $3.17 GENE Score: -22.92

Market geography.

Recs

0
Member Avatar larryhamilton (< 20) Submitted: 11/5/2015 11:28:21 AM : Outperform Start Price: $3.30 GENE Score: -25.05

$GENE Read SEC filings, this company is not crap. 2016 brings lots of positive BGP approvals. Holding a 15% stake in the company.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 9/8/2014 1:06:42 PM : Underperform Start Price: $3.30 GENE Score: +29.65

cash flow is not good

Recs

0
Member Avatar red1582 (34.53) Submitted: 11/16/2012 11:52:49 AM : Underperform Start Price: $12.90 GENE Score: +132.80

100% Sell Signal
Gaped Down

Recs

1
Member Avatar MarkSmithJr777 (< 20) Submitted: 7/20/2011 7:34:41 PM : Underperform Start Price: $38.50 GENE Score: +147.10

Coming down

Recs

0
Member Avatar ferdicemara (< 20) Submitted: 5/15/2011 11:38:11 AM : Outperform Start Price: $38.65 GENE Score: -148.22

success

Recs

0
Member Avatar Lifeguru (64.85) Submitted: 4/9/2007 5:00:09 PM : Underperform Start Price: $35.50 GENE Score: +144.31

Junk

Recs

0
Member Avatar ctolbert (79.31) Submitted: 4/6/2007 7:39:22 PM : Underperform Start Price: $29.55 GENE Score: +142.62

Genetics companies are a hard sell and are too susceptible to market news to bank on.

Results 1 - 8 of 8

Featured Broker Partners